My watch list

Bromopride


Bromopride
Systematic (IUPAC) name
4-amino-5-bromo-N-(2-diethylaminoethyl)- 2-methoxybenzamide
Identifiers
CAS number	4093-35-0
ATC code	A03FA04
PubChem	2446
Chemical data
Formula	C₁₄H₂₂BrN₃O₂
Mol. mass	344.248 g/mol
Pharmacokinetic data
Bioavailability	50 to 75% (oral) 78% (intramuscular)
Protein binding	40%
Metabolism	Hepatic
Half life	4 to 5 hours
Excretion	Renal, 10 to 14% unchanged
Therapeutic considerations
Pregnancy cat.	?
Legal status	Red Label (BR)
Routes	Oral, IM, IV

Bromopride (INN) is a dopamine antagonist with prokinetic properties widely used as an antiemetic, closely related to metoclopramide. It is not available in the United States.

Bromopride appears to be safe and effective for use in pregnancy.^[1]

Additional recommended knowledge

Safe Weighing Range Ensures Accurate Results

Essential Laboratory Skills Guide

Guide to balance cleaning: 8 simple steps

1 Indications
2 Adverse effects
3 Chemistry
4 Availability
5 References

Indications

Bromopride is indicated in the treatment of nausea and vomiting, including postoperative nausea and vomiting (PONV); gastroesophageal reflux disease (GERD/GORD); and as preparation for endoscopy and radiographic studies of the gastrointestinal tract. The manufacturer also claims it is valuable in, among other indications, hiccups and gastrointestinal adverse effects of radiation therapy.

Adverse effects

Bromopride is generally well tolerated; the most common adverse effects of its use are somnolence and fatigue. Bromopride may rarely cause extrapyramidal symptoms and, as metoclopramide, may increase prolactin levels.^[2]

Chemistry

Bromopride is a substituted benzamide, closely related to metoclopramide.^[3] It is identical to metoclopramide except for the presence of a bromine atom where metoclopramide has a chlorine substituent.

Availability

Bromopride is not available in the United States or the United Kingdom. It is marketed in Brazil by Sanofi-Synthélabo under the trade name Digesan and as a generic drug.

References

^ Araújo JR (1981). "Evaluation of bromopride in nausea and vomiting of pregnancy" (in Portuguese). J Bras Ginecol 91 (4): 283–5.
^ Bula do Profissional de Saúde: Bromoprida (Portuguese). Bulário Eletrônico da Anvisa. Brazilian National Health Surveillance Agency (April 11 2006). Retrieved on 2007-07-23.
^ Brodie RR, Chasseaud LF, Darragh A, Lambe RF, Rooney L, Taylor T (1986). "Pharmacokinetics and bioavailability of the anti-emetic agent bromopride". Biopharm Drug Dispos 7 (3): 215–22. doi:10.1002/bdd.2510070302. PMID 3730521.

v • d • e

Drugs for functional gastrointestinal disorders (A03)

Drugs for functional bowel disorders

antimuscarinics: Mebeverine - Dicycloverine - Propantheline

papaverine and derivatives: Papaverine - Drotaverine - Moxaverine

acting on serotonin receptors: 5-HT₃ antagonists (Alosetron, Cilansetron) - 5HT₄ agonists (Mosapride, Tegaserod)

other: Diisopromine - Isometheptene - Phloroglucinol - Proglumide - Tridihexethyl

Belladonna and derivatives
(antimuscarinics)

Atropine - Hyoscyamine - Butylscopolamine - Methylscopolamine

Propulsives

primarily dopamine antagonists (Metoclopramide/Bromopride, Domperidone, Alizapride) - serotonin agonists (Cisapride) - Clebopride

Categories: Antiemetics | Dopamine antagonists | Motility stimulants

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Bromopride". A list of authors is available in Wikipedia.